ELAN LICENSING TRANSDERMAL NICOTINE PATCH WORLDWIDE RIGHTS
Executive Summary
ELAN LICENSING TRANSDERMAL NICOTINE PATCH WORLDWIDE RIGHTS to "a major U.S. multinational pharmaceutical corporation," the Irish firm announced May 5. "This product represents an instance in which Elan developed a product of its own choosing to capitalize upon a unique market opportunity," the release states. "Until recently, we developed important drug reformulations under client-funded research projects." Elan said it plans to begin clinical testing in Ireland "shortly" and that its licensing partner would likely initiate clinical trials in the U.S. Under the agreement, Elan retains the rights to market the once-a-day smoking cessation product in Ireland and Southeast Asia. "Management anticipates that royalties and manufacturing fees it will receive under the licensing arrangement will have a significant impact on Elan's future revenues," Elan Chairman Donald Panoz said. "Marketing studies by our licensee and provided to us indicate that a transdermal nicotine patch which successfully meets certain performance specifications . . . would have a major impact on the worldwide smoking cessation market." The patch product, which employs Elan's proprietary Dermaflex and Panoderm transdermal technology, maintains regular levels of nicotine in the blood and thereby eliminates the need to smoke a cigarette, according to the release. "By employing a succession of lower strength nicotine patches over several weeks or months," Elan explained, "the nicotine level in the blood is gradually lowered, thus reducing nicotine dependency." When approved in the U.S., the product will compete with Merrell Dow's Nicorette. Approved in 1984, Nicorette had retail sales of $34 mil. (at pharmacy acquisition cost) in 10 months on the market, according to the Rx audit firm Pharmaceutical Data Services. Elan's current licensing agreements with U.S. firms include arrangements with Pfizer and Riker, covering sustained release formulations of nifedipine and theophylline, respectively.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth